Protein binding of antimicrobials: Methods for quantification and for investigation of its impact on bacterial kill

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 1-12

  Beer, Jürgen ^a   Wagner, Claudia Christina ^a   Zeitlinger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antimicrobials; Pharmacodynamics; Protein binding

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFDITOREN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DAPTOMYCIN; FUSIDIC ACID; ICLAPRIM; MOXIFLOXACIN; OXACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERICIDAL ACTIVITY; CAPILLARY ELECTROPHORESIS; CHROMATOGRAPHY; CULTURE MEDIUM; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; ENTEROCOCCUS FAECIUM; EQUILIBRIUM DIALYSIS; FLUORESCENCE SPECTROSCOPY; IN VITRO STUDY; MATHEMATICAL MODEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; QUANTITATIVE STUDY; REVIEW; STANDARDIZATION; ULTRACENTRIFUGATION; ULTRAFILTRATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIA; BLOOD PROTEINS; BODY FLUIDS; CHEMISTRY, ANALYTICAL; CULTURE MEDIA; DRUG RESISTANCE, MICROBIAL; HUMANS; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; TIME FACTORS;

EID: 65549166912     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9072-1     Document Type: Review

References (76)

1. J. Oravcova, B. Bohs, and W. Lindner. Drug-protein binding sites. New trends in analytical and experimental methodology. J. Chromatogr. B Biomed. Appl. 677(1):1-28 (1996) Feb 23.
2. J. D. Wright, F. D. Boudinot, and M. R. Ujhelyi. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet. 30(6):445-462 (1996) Jun.
3. E. Bergogne-Berezin. Clinical role of protein binding of quinolones. Clin Pharmacokinet. 41(10):741-750 (2002).
4. J. Turnidge. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 58(Suppl 2):29-36 (1999).
5. C. M. Kunin. Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin. Pharmacol. Ther. 7(2):166-179 (1966) Mar-Apr.
6. C. M. Kunin, W. A. Craig, M. Kornguth, and R. Monson. Influence of binding on the pharmacologic activity of antibiotics. Ann. N Y Acad. Sci. 226:214-224 (1973) Nov 26.
7. R. Cha, and M. J. Rybak. Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 54(1):259-262 (2004) Jul.
8. E. Rubinstein, L. Diamantstein G. Yoseph et al. The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. Clin. Microbiol. Infect. 6(12):678-681 (2000) Dec.
9. M. Zeitlinger, R. Sauermann, M. Fille, J. Hausdorfer, I. Leitner, and M. Muller. Plasma protein binding of fluoroquinolones affects antimicrobial activity. J. Antimicrob. Chemother. 61(3):561-567 (2008) Mar.
10. T. Bergan, A. Engeset, and W. Olszewski. Does serum protein binding inhibit tissue penetration of antibiotics? Rev. Infect. Dis. 9(4):713-718 (1987) Jul-Aug.
11. W. A. Craig, and S. C. Ebert. Protein binding and its significance in antibacterial therapy. Infect. Dis. Clin. North Am. 3(3):407-414 (1989) Sep.
12. W. A. Craig, and P. G. Welling. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 2(4):252-268 (1977) Jul-Aug.
13. L. R. Peterson, and D. N. Gerding. Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concepts. Rev. Infect. Dis. 2(3):340-348 (1980) May-Jun.
14. R. T. Scheife. Protein binding: What does it mean? DICP. 23(7-8 Suppl):S27-31 (1989) Jul-Aug.
15. W. A. Craig, and C. M. Kunin. Significance of serum protein and tissue binding of antimicrobial agents. Annu. Rev. Med. 27:287-300 (1976).
16. D. J. Merrikin, J. Briant, and G. N. Rolinson. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother. 11(3):233-238 (1983) Mar.
17. R. Wise. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin. Pharmacokinet. 11(6):470-482 (1986) Nov-Dec.
18. R. Wise. Protein binding of beta-lactams: The effects on activity and pharmacology particularly tissue penetration. II. Studies in man. J. Antimicrob. Chemother. 12(2):105-118 (1983) Aug.
19. W. E. Lindup, and M. C. Orme. Clinical pharmacology: Plasma protein binding of drugs. Br. Med. J. (Clin Res Ed). 282(6259):212-214 (1981) Jan 17.
20. Y. Yano, T. Oguma, H. Nagata, and S. Sasaki. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J. Pharm. Sci. 87(10):1177-1183 (1998) Oct.
21. O. Burkhardt, M. Brunner, S. Schmidt, M. Grant, Y. Tang, and H. Derendorf. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J. Antimicrob. Chemother. 58(3):632-636 (2006) Sep.
22. T. R. Perry, and J. J. Schentag. Clinical use of ceftriaxone: A pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin. Pharmacokinet. 40(9):685-694 (2001).
23. R. Mehrotra, R. De Gaudio, and M. Palazzo. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 30(12):2145-2156 (2004) Dec.
24. L. Z. Benet, and B. A. Hoener. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71(3):115-121 (2002) Mar.
25. A. Dasgupta. Clinical utility of free drug monitoring. Clin. Chem. Lab. Med. 40(10):986-993 (2002) Oct.
26. H. Kurz, H. Trunk, and B. Weitz. Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneimittelforschung. 27(7):1373-1380 (1977) Jul.
27. Z. J. Lin, D. Musiano, A. Abbot, and L. Shum. In vitro plasma protein binding determination of flunarizine using equilibrium dialysis and liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 37(4):757-762 (2005) Apr 1.
28. W. Scholtan. [Methods of determination and theoretical principles of the serum protein binding of drugs (author's transl)]. Arzneimittelforschung. 28(7):1037-1047 (1978).
29. B. Sebille. Methods of drug protein binding determinations. Fundam. Clin. Pharmacol. 4(Suppl 2):151s-161s (1990).
30. H. Wan, and M. Rehngren. High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry. J. Chromatogr. A. 1102(1-2):125-134 (2006) Jan 13.
31. C. Joukhadar, and M. Muller. Microdialysis: Current applications in clinical pharmacokinetic studies and its potential role in the future. Clin. Pharmacokinet. 44(9):895-913 (2005).
32. A. Le Quellec, S. Dupin, A. E. Tufenkji, P. Genissel, and G. Houin. Microdialysis: An alternative for in vitro and in vivo protein binding studies. Pharm. Res. 11(6):835-838 (1994) Jun.
33. M. Stahl, R. Bouw, A. Jackson, and V. Pay. Human microdialysis. Curr. Pharm. Biotechnol. 3(2):165-178 (2002) Jun.
34. R. K. Verbeeck. Blood microdialysis in pharmacokinetic and drug metabolism studies. Adv. Drug Deliv. Rev. 45(2-3):217-228 (2000) Dec 15.
35. A. Heinze, and U. Holzgrabe. Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method. In.t J. Pharm. 311(1-2):108-112 (2006) Mar 27.
36. J. B. Whitlam, and K. F. Brown. Ultrafiltration in serum protein binding determinations. J. Pharm. Sci. 70(2):146-150 (1981) Feb.
37. Y. Matsushita, and I. Moriguchi. Measurement of protein binding by ultracentrifugation. Chem. Pharm. Bull. (Tokyo). 33(7):2948-2955 (1985) Jul.
38. D. S. Hage. Chromatographic and electrophoretic studies of protein binding to chiral solutes. J. Chromatogr. A. 906(1-2):459-481 (2001) Jan 12.
39. B. H. Ackerman, E. H. Taylor, K. M. Olsen, W. Abdel-Malak, and A. A. Pappas. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell. Clin. Pharm. 22(4):300-303 (1988) Apr.
40. I. Gastearena, M. C. Dios-Vieitez, M. M. Terraz, S. Domingo, and D. Fos. Determination of the alpha1-acid glycoprotein binding of azithromycin in vitro by equilibrium dialysis. J. Chemother. 7(Suppl 4):26-28 (1995) Nov.
41. J. E. Hutchins, K. Tyczkowska, and A. L. Aronson. Determination of ampicillin in serum by using simple ultrafiltration technique and liquid chromatographic analysis. J. Assoc. Off. Anal. Chem. 69(5):757-759 (1986) Sep-Oct.
42. H. Teraoka, and K. H. Nierhaus. Measurement of the binding of antibiotics to ribosomal particles by means of equilibrium dialysis. Methods Enzymol. 59:862-866 (1979).
43. T. H. Tsai, F. C. Cheng, L. C. Hung, and C. F. Chen. Determination of unbound ceftriaxone in rat blood by on-line microdialysis and microbore liquid chromatography. Int. J. Pharm. 193(1):21-26 (1999) Dec 20.
44. S. Schmidt, K. Rock M. Sahre et al. The effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob. Agents Chemother. 52(11):3994-4000 (2008).
45. F. Traunmuller, M. Zeitlinger, P. Zeleny, M. Muller, and C. Joukhadar. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrob. Agents Chemother. 51(9):3185-3189 (2007) Sep.
46. S. M. Palmer, S. L. Kang, D. M. Cappelletty, and M. J. Rybak. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob. Agents Chemother. 39(8):1764-1771 (1995) Aug.
47. D. Sevillano, M. J. Gimenez L. Alou et al. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 60(1):156-158 (2007) Jul.
48. M. A. Zeitlinger, R. Sauermann, F. Traunmuller, A. Georgopoulos, M. Muller, and C. Joukhadar. Impact of plasma protein binding on antimicrobial activity using time-killing curves. J. Antimicrob. Chemother. 54(5):876-880 (2004) Nov.
49. F. Cafini, L. Aguilar N. Gonzalez et al. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J. Antimicrob. Chemother. 59(6):1185-1189 (2007) Jun.
50. B. T. Tsuji, S. N. Leonard, P. R. Rhomberg, R. N. Jones, and M. J. Rybak. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn. Microbiol. Infect. Dis. 60(4):441-444 (2008).
51. H. Laue, T. Valensise, A. Seguin, S. Hawser, S. Lociuro, and K. Islam. Effect of human plasma on the antimicrobial activity of iclaprim in vitro. J. Antimicrob. Chemother. 60(6):1388-1390 (2007) Dec.
52. J. M. Woodcock, J. M. Andrews, N. P. Brenwald, J. P. Ashby, and R. Wise. The in-vitro activity of faropenem, a novel oral penem. J. Antimicrob. Chemother. 39(1):35-43 (1997) Jan.
53. L. R. Peterson, and C. J. Shanholtzer. Tests for bactericidal effects of antimicrobial agents: Technical performance and clinical relevance. Clin. Microbiol. Rev. 5(4):420-432 (1992) Oct.
54. N. C. f. C. L. Standards. Methods for determining bactericidal activity of antimicrobial agents. Document M26-P. In: Stand. NCCL, ed. 7(2):35-76; 1987.
55. I. P. Balcabao, L. Alou, L. Aguilar, M. L. Gomez-Lus, M. J. Gimenez, and J. Prieto. Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones. J. Antimicrob. Chemother. 48(6):907-909 (2001) Dec.
56. B. Bedenic. Selection of Klebsiella pneumoniae mutants with high-level cefotaxime resistance during growth in serum containing therapeutic concentrations of cefotaxime. Chemotherapy. 48(1):10-14 (2002) Mar.
57. F. J. Boswell, J. P. Ashby, J. M. Andrews, and R. Wise. Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem. J. Antimicrob. Chemother. 50(4):525-532 (2002) Oct.
58. J. R. Edwards. Cefotetan: Antibacterial activity against Staphylococcus aureus in the presence of human serum. Chemioterapia. 7(4):271-273 (1988) Aug.
59. I. Gustafsson, and O. Cars. The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae. Clin. Microbiol. Infect. 10(10):934-937 (2004) Oct.
60. K. D. Leuthner, C. M. Cheung, and M. J. Rybak. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(2):338-343 (2006) Aug.
61. D. E. Nix, K. R. Matthias, and E. C. Ferguson. Effect of ertapenem protein binding on killing of bacteria. Antimicrob. Agents Chemother. 48(9):3419-3424 (2004) Sep.
62. I. Odenholt, E. Lowdin, and O. Cars. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob. Agents Chemother. 51(9):3311-3316 (2007) Sep.
63. T. M. Perl, M. A. Pfaller, A. Houston, and R. P. Wenzel. Effect of serum on the in vitro activities of 11 broad-spectrum antibiotics. Antimicrob. Agents Chemother. 34(11):2234-2239 (1990) Nov.
64. F. J. Schmitz, M. Boos, S. Mayer, J. Verhoef, D. Milatovic, and A. C. Fluit. In vitro activity of faropenem and 20 other compounds against beta-lactamase-positive and -negative Moraxella catarrhalis and Haemophilus influenzae isolates and the effect of serum on faropenem MICs. J. Antimicrob. Chemother. 49(1):220-223 (2002) Jan.
65. R. Wise. Protein binding of beta-lactams: The effects on activity and pharmacology particularly tissue penetration. I. J. Antimicrob. Chemother. 12(1):1-18 (1983) Jul.
66. M. Pistolozzi, and C. Bertucci. Species-dependent stereoselective drug binding to albumin: A circular dichroism study. Chirality. 20(3-4):552-558 (2008) Mar.
67. B. T. Tsuji, and M. J. Rybak. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 49(7):2735-2745 (2005) Jul.
68. A. Louie, P. Kaw, W. Liu, N. Jumbe, M. H. Miller, and G. L. Drusano. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45(3):845-851 (2001) Mar.
69. I. Lutsar, and I. R. Friedland. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin. Pharmacokinet. 39(5):335-343 (2000) Nov.
70. J. Aagaard, T. Gasser, P. Rhodes, and P. O. Madsen. MICs of ciprofloxacin and trimethoprim for Escherichia coli: Influence of pH, inoculum size and various body fluids. Infection. 19(Suppl 3):S167-169 (1991).
71. G. G. Zhanel, J. A. Karlowsky, R. J. Davidson, and D. J. Hoban. Influence of human urine on the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli. Chemotherapy. 37(3):218-223 (1991).
72. M. Mueller, A. de la Pena, and H. Derendorf. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Kill curves versus MIC. Antimicrob. Agents Chemother. 48(2):369-377 (2004) Feb.
73. C. W. Stratton, L. S. Weeks, and K. E. Aldridge. Comparison of kill-kinetic studies with agar and broth microdilution methods for determination of antimicrobial activity of selected agents against members of the Bacteroides fragilis group. J. Clin. Microbiol. 25(4):645-649 (1987) Apr.
74. R. Sauermann, G. Delle-Karth C. Marsik et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob. Agents Chemother. 49(2):650-655 (2005) Feb.
75. M. A. Zeitlinger, B. M. Erovic, R. Sauermann, A. Georgopoulos, M. Muller, and C. Joukhadar. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. J. Antimicrob. Chemother. 56(4):703-708 (2005) Oct.
76. R. Sauermann, G. Delle-Karth C. Marsik et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob. Agents Chemother. 49(2):650-655 (2005) Feb.